普萘洛尔治疗婴幼儿呼吸道血管瘤的疗效分析

Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children

摘要:

目的 分析口服普萘洛尔治疗婴幼儿呼吸道血管瘤的效果。方法 回顾性分析2012年11月至2019年12月收治的、经支气管镜及喉部平扫增强CT/MRI确诊、且口服普萘洛尔治疗的婴幼儿呼吸道血管瘤患儿的临床资料。结果 共纳入20例患儿，所有患儿口服普萘洛尔治疗1~2 d后喉喘鸣、呼吸困难等症状均有改善，中位治疗时间为10个月（范围：6~12个月）。中位随访时间为10个月（范围：3~15个月）。19例（95%）患儿瘤体基本消退；1例（5%）患儿停药6个月后复查瘤体较停药前增大，予增加普萘洛尔剂量治疗6个月后，病情未出现反复；仅1例（5%）患儿出现不良反应；1例（5%）患儿尚在治疗中。结论 口服普萘洛尔可快速缓解呼吸困难等症状，使瘤体消退，不良反应少，可有效治疗婴幼儿呼吸道血管瘤。

Abstract:

Objective To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children. Methods A retrospective analysis was performed from the chart review data of children with respiratory hemangioma treated by oral propranolol and diagnosed by bronchoscopy and laryngeal plain enhanced CT/MRI from November 2012 to December 2019. Results A total of 20 children were enrolled. All children had improvement in the symptoms of laryngeal stridor and dyspnea after oral administration of propranolol for 1-2 days. The median treatment time was 10 months (range 6-12 months). The median follow-up time was 10 months (range 3-15 months). Of the 20 children, 19 (95%) achieved regression of tumor, and 1 (5%) experienced an increase in tumor size during reexamination at 6 months after drug withdrawal and had no recurrence after the treatment with an increased dose of propranolol for 6 months. Only 1 child (5%) had adverse reactions, and 1 child (5%) was still under treatment. Conclusions Oral propranolol can quickly relieve the symptoms such as dyspnea and achieve tumor regression, with few adverse events, and it is therefore an effective method for the treatment of respiratory hemangioma in infants and young children.